

<b>Statistical analysis title</b>	Cohort 1, ACP: Fesoterodine 4 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 4 mg
Number of subjects included in analysis	15
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.7986
Method	ANCOVA
Confidence interval	
<b>Statistical analysis title</b>	Cohort 1, ACP: Fesoterodine 8 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 8 mg

Number of subjects included in analysis	15
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.2313
Method	ANCOVA
Confidence interval	
<b>Statistical analysis title</b>	Cohort 1, ACP: Oxybutynin
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline mean volume voided per micturition and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Oxybutynin
Number of subjects included in analysis	20
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.7571

Method	ANCOVA
Confidence interval	